183 related articles for article (PubMed ID: 11277176)
1. Prognostic significance of the immunocytochemical detection of contaminating tumor cells (CTC) in apheresis products of patients with high-risk breast cancer treated with high-dose chemotherapy and stem cell transplantation.
Solano C; Badia B; Lluch A; Marugan I; Benet I; Arbona C; Prosper F; García-Conde J
Bone Marrow Transplant; 2001 Feb; 27(3):287-93. PubMed ID: 11277176
[TBL] [Abstract][Full Text] [Related]
2. High-dose chemotherapy in patients with breast cancer: evaluation of infusing peripheral blood stem cells containing occult tumor cells.
Weaver CH; Moss T; Schwartzberg LS; Zhen B; West J; Rhinehart S; Campos L; Beeker T; Lautersztain L; Messino M; Buckner CD
Bone Marrow Transplant; 1998 Jun; 21(11):1117-24. PubMed ID: 9645574
[TBL] [Abstract][Full Text] [Related]
3. [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study].
Shi Y; Pan F; Han X
Zhonghua Yi Xue Za Zhi; 1999 Dec; 79(12):890-3. PubMed ID: 11715500
[TBL] [Abstract][Full Text] [Related]
4. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
Cheng YC; Rondón G; Yang Y; Smith TL; Gajewski JL; Donato ML; Shpall EJ; Jones R; Hortobagyi GN; Champlin RE; Ueno NT
Biol Blood Marrow Transplant; 2004 Nov; 10(11):794-804. PubMed ID: 15505610
[TBL] [Abstract][Full Text] [Related]
5. Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.
Hohaus S; Funk L; Martin S; Schlenk RF; Abdallah A; Hahn U; Egerer G; Goldschmidt H; Schneeweiss A; Fersis N; Kaul S; Wallwiener D; Bastert G; Haas R
Br J Cancer; 1999 Mar; 79(9-10):1500-7. PubMed ID: 10188897
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of the detection of tumour cells in peripheral blood stem cell collections in stage II and III breast cancer patients treated with high-dose therapy.
Patriarca F; Sacco C; Sperotto A; Geromin A; Damiani D; Fili C; Cerno M; Clochiatti L; Cartei G; Fanin R
Bone Marrow Transplant; 2003 May; 31(9):789-94. PubMed ID: 12732886
[TBL] [Abstract][Full Text] [Related]
7. Micrometastases in apheresis products predict shorter progression-free and overall survival in patients with breast cancer undergoing high-dose chemotherapy (HDCT) and autologous blood stem cell transplantation (ABSCT).
Syme R; Stewart D; Rodriguez-Galvez M; Luider J; Auer Y; Klassen J; Morris D; Brown C; Russell J; Glück S
Bone Marrow Transplant; 2003 Aug; 32(3):307-11. PubMed ID: 12858203
[TBL] [Abstract][Full Text] [Related]
8. Occult tumor cells detected in autologous blood stem cell harvests have no impact on 5 year outcomes for breast cancer patients with 4-9 positive nodes treated with adjuvant high-dose therapy and stem cell transplantation.
Reed E; Kessinger A; Murphy B; Tarantolo S; Traystman M; Sharp JG
Bone Marrow Transplant; 2003 Apr; 31(7):571-4. PubMed ID: 12692623
[TBL] [Abstract][Full Text] [Related]
9. [High dosage therapy and autologous peripheral stem cell transplantation in breast carcinoma].
Kier P; Ruckser R; Buxhofer V; Habertheuer KH; Zelenka P; Tatzreiter G; Hübl G; Kittl E; Hauser A; Sebesta C; Hinterberger W
Acta Med Austriaca Suppl; 2000; 52():33-6. PubMed ID: 11261276
[TBL] [Abstract][Full Text] [Related]
10. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR
Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302
[TBL] [Abstract][Full Text] [Related]
11. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support.
Vredenburgh JJ; Silva O; Broadwater G; Berry D; DeSombre K; Tyer C; Petros WP; Peters WP; Bast RC
Biol Blood Marrow Transplant; 1997 Jun; 3(2):91-7. PubMed ID: 9267669
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
Hanrahan EO; Broglio K; Frye D; Buzdar AU; Theriault RL; Valero V; Booser DJ; Singletary SE; Strom EA; Gajewski JL; Champlin RE; Hortobagyi GN
Cancer; 2006 Jun; 106(11):2327-36. PubMed ID: 16639731
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
14. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
15. Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplatation in metastatic breast cancer results in survival benefit.
Kurian S; Qazilbash M; Fay J; Wolff S; Herzig R; Hobbs G; Bunner P; Weisenborn R; Aya-Ay M; Lynch J; Ericson S
Breast J; 2006; 12(6):531-5. PubMed ID: 17238982
[TBL] [Abstract][Full Text] [Related]
16. High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer.
Gutierrez-Delgado F; Holmberg LA; Hooper H; Appelbaum FR; Livingston RB; Maziarz RT; Weiden P; Rivkin S; Montgomery P; Kawahara K; Bensinger W
Bone Marrow Transplant; 2000 Jul; 26(1):51-9. PubMed ID: 10918405
[TBL] [Abstract][Full Text] [Related]
17. The clinical significance of tumor cells in bone marrow or apheresis product and the efficacy of CD34+ selection and high-dose chemotherapy in patients with Stage III breast cancer.
Arpaci F; Safali M; Ozet A; Ural AU; Cetin T; Ozturk M; Ataergin S; Kuzhan O; Komurcu S; Ozturk B; Acikel C
J Clin Apher; 2009; 24(5):197-204. PubMed ID: 19816961
[TBL] [Abstract][Full Text] [Related]
18. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant.
Nieto Y; Cagnoni PJ; Shpall EJ; Xu X; Murphy J; Vredenburgh J; Chao NJ; Bearman SI; Jones RB
Clin Cancer Res; 1999 Nov; 5(11):3425-31. PubMed ID: 10589754
[TBL] [Abstract][Full Text] [Related]
19. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
20. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
